Search for content, post, videos

Boule Diagnostics appoints new CEO & President

The board of directors at Boule Diagnostics has appointed Torben Nielsen as the new CEO and President, effective no later than June 14, 2024.

Torben Nielsen will replace Jesper Söderqvist, who has been the CEO since 2020. Jesper will be available to the company during a transition period and will leave his position at latest by April 15, 2024. If necessary, the company’s CFO, Holger Lembrér, will act as interim CEO until Torben Nielsen assumes his role.

“Torben Nielsen, with his extensive experience in international sales, not only within segments closely related to Boule’s markets but also in other healthcare markets with a similar business model, will make a significant contribution. We are facing a product launch of a new hematology platform, increased focus on the veterinary segment, and expansion of our OEM business,” adds Torben Jörgensen, Chairman of the Board at Boule Diagnostics.

Torben Nielsen

Torben Nielsen most recently held the position as Executive Vice President in the Analytical Solutions and Customer Enablement business area at PerkinElmer. He brings extensive experience from the hematology market, having worked at Radiometer from 2005 to 2019. His roles included General Manager for Radiometer America and previously Sales Manager for Western Europe. Nielsen also has broader experience in the medical technology industry, having served as Sales Manager for EMEA in the subsidiary companies Ormco and Spark within the Envista group.

“I am very much looking forward to taking on the role of CEO at Boule Diagnostics, a company with a strong market position, brands associated with robustness and quality, and many loyal customers. Boule benefits from several global trends. With a new product platform and excellent opportunities to further develop and expand the business, I am excited to take the company to the next level,” says Torben Nielsen, the incoming CEO of Boule Diagnostics.